KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19.

Oliver J McElvaney, Natalie L McEvoy, Fiona Boland, Oisín F McElvaney, Grace Hogan, Karen Donnelly, Oisín Friel, Emmet Browne, Daniel D Fraughen, Mark P Murphy, Jennifer Clarke, Orna Ní Choileáin, Eoin O'Connor, Rory McGuinness, Maria Boylan, Alan Kelly, John C Hayden, Ann M Collins, Ailbhe Cullen, Deirdre Hyland, Tomás P Carroll, Pierce Geoghegan, John G Laffey, Martina Hennessy, Ignacio Martin-Loeches, Noel G McElvaney, Gerard F Curley

Med 3(4) 233-248.e6

PMID35291694
PMCIDPMC8913266
DOI10.1016/j.medj.2022.03.001
发表日期2022-03-16
摘要

摘要

BACKGROUND: Patients with severe coronavirus disease 2019 (COVID-19) develop a febrile pro-inflammatory cytokinemia with accelerated progression to acute respiratory distress syndrome (ARDS). Here we report the results of a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of intravenous (IV) plasma-purified alpha-1 antitrypsin (AAT) for moderate to severe ARDS secondary to COVID-19 (EudraCT 2020-001391-15). METHODS: Patients (n = 36) were randomized to receive weekly placebo, weekly AAT (Prolastin, Grifols, S.A.; 120 mg/kg), or AAT once followed by weekly placebo. The primary endpoint was the change in plasma interleukin (IL)-6 concentration at 1 week. In addition to assessing safety and tolerability, changes in plasma levels of IL-1β, IL-8, IL-10, and soluble tumor necrosis factor receptor 1 (sTNFR1) and clinical outcomes were assessed as secondary endpoints. FINDINGS: Treatment with IV AAT resulted in decreased inflammation and was safe and well tolerated. The study met its primary endpoint, with decreased circulating IL-6 concentrations at 1 week in the treatment group. This was in contrast to the placebo group, where IL-6 was increased. Similarly, plasma sTNFR1 was substantially decreased in the treatment group while remaining unchanged in patients receiving placebo. IV AAT did not definitively reduce levels of IL-1β, IL-8, and IL-10. No difference in mortality or ventilator-free days was observed between groups, although a trend toward decreased time on ventilator was observed in AAT-treated patients. CONCLUSIONS: In patients with COVID-19 and moderate to severe ARDS, treatment with IV AAT was safe, feasible, and biochemically efficacious. The data support progression to a phase 3 trial and prompt further investigation of AAT as an anti-inflammatory therapeutic. FUNDING: ECSA-2020-009; Elaine Galwey Research Bursary.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。